A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
The purpose of this study is to test the effectiveness, safety, and tolerability of ziprasidone (Geodon) as a treatment for Major Depressive Disorder (MDD). Ziprasidone has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of bipolar disorder and schizophrenia, but in this study it is being tested for its effectiveness in depression.
As a subject in this research study you will be randomly assigned by chance, like the flip of a coin, to one of three groups. Subjects in the first group will receive 12 weeks of ziprasidone, those in the second group will receive 12 weeks of placebo (looks like the study drug but contains no active medication), and those in the third group will receive 6 weeks of placebo followed by 6 weeks of ziprasidone. You will have a 5 in 8 chance of receiving ziprasidone at some point in the study.
It will take you about 14 weeks to complete this study. During this time you will be asked to make 14 study visits. At the conclusion of the study, you will be offered 3 months of follow-up care at no cost with the study physicians on staff.
If you are interested in this study, please contact Carrie Brintz at 617-726-5805 or cbrintz@partners.org
We initiate new studies regularly, so please contact us for additional information.